NasdaqCM:GALT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Galectin Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GALT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.2%

GALT

-2.5%

US Biotechs

-4.1%

US Market


1 Year Return

-34.8%

GALT

25.0%

US Biotechs

12.0%

US Market

Return vs Industry: GALT underperformed the US Biotechs industry which returned 25% over the past year.

Return vs Market: GALT underperformed the US Market which returned 12% over the past year.


Shareholder returns

GALTIndustryMarket
7 Day-2.2%-2.5%-4.1%
30 Day-2.2%-2.1%-0.2%
90 Day0%-1.8%2.8%
1 Year-34.8%-34.8%27.1%25.0%14.6%12.0%
3 Year5.7%5.7%18.0%12.0%35.8%26.8%
5 Year-5.1%-5.1%8.9%1.0%75.2%55.6%

Price Volatility Vs. Market

How volatile is Galectin Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Galectin Therapeutics undervalued compared to its fair value and its price relative to the market?

4.28x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GALT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GALT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GALT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: GALT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GALT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GALT is overvalued based on its PB Ratio (4.3x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Galectin Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

35.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GALT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GALT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GALT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if GALT's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if GALT's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GALT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Galectin Therapeutics performed over the past 5 years?

5.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GALT is currently unprofitable.

Growing Profit Margin: GALT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GALT is unprofitable, but has reduced losses over the past 5 years at a rate of 5.3% per year.

Accelerating Growth: Unable to compare GALT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.8%).


Return on Equity

High ROE: GALT has a negative Return on Equity (-47.53%), as it is currently unprofitable.


Next Steps

Financial Health

How is Galectin Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: GALT's short term assets ($41.1M) exceed its short term liabilities ($4.3M).

Long Term Liabilities: GALT's short term assets ($41.1M) exceed its long term liabilities ($31.0K).


Debt to Equity History and Analysis

Debt Level: GALT is debt free.

Reducing Debt: GALT has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GALT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: GALT has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 3.6% each year.


Next Steps

Dividend

What is Galectin Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GALT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GALT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GALT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average management tenure


CEO

Joel Lewis (50 yo)

0.083

Tenure

US$189,098

Compensation

Mr. Joel Lewis serves as Chief Executive Officer and President at Galectin Therapeutics, Inc since September 2, 2020 and Director since December 14, 2017. He served as the Managing Director of Shareholder ...


Leadership Team

NamePositionTenureCompensationOwnership
Joel Lewis
President0.083yrUS$189.10k0.19%
$ 279.5k
Jack Callicutt
CFO, Treasurer & Secretary7.25yrsUS$778.12k0.0074%
$ 11.0k
Harold Shlevin
Consultant & Director0.83yrUS$1.31m0.015%
$ 22.7k
Robert Tritt
General Counselno datano datano data
Eliezer Zomer
Executive Vice President of Manufacturing & Product Development20.75yrsUS$134.47kno data
Pol Boudes
Chief Medical Officer0.58yrno datano data

0.6yrs

Average Tenure

63yo

Average Age

Experienced Management: GALT's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Joel Lewis
President0.083yrUS$189.10k0.19%
$ 279.5k
Harold Shlevin
Consultant & Director0.83yrUS$1.31m0.015%
$ 22.7k
Gilbert Amelio
Independent Director11.58yrsUS$181.10k0.22%
$ 325.2k
Gilbert Omenn
Independent Director6.08yrsUS$179.10k0.14%
$ 208.1k
James Czirr
Director11.58yrsUS$134.28k1.35%
$ 2.0m
Richard Uihlein
Independent Chairman2.42yrsUS$188.26k13.89%
$ 20.7m
Marc Rubin
Independent Director9yrsUS$134.28k0.024%
$ 35.4k
Anatole Klyosov
Co-founder & Member of the Scientific Boardno dataUS$203.69kno data
Kevin Mayo
Member of the Scientific Boardno datano datano data
Kevin Freeman
Independent Vice Chairman of the Board2.75yrsUS$199.26k0.11%
$ 168.3k
Naga Chalasani
Member of Clinical Advisory Boardno datano datano data
Richard Zordani
Independent Director0.083yrno data0.027%
$ 40.1k

2.8yrs

Average Tenure

68yo

Average Age

Experienced Board: GALT's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: GALT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Galectin Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Galectin Therapeutics, Inc.
  • Ticker: GALT
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$148.971m
  • Shares outstanding: 57.08m
  • Website: https://galectintherapeutics.com

Number of Employees


Location

  • Galectin Therapeutics, Inc.
  • 4960 Peachtree Industrial Boulevard
  • Suite 240
  • Norcross
  • Georgia
  • 30071
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GALTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2002
PHPNDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2002

Biography

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company’s lead product candidate i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/30 03:48
End of Day Share Price2020/10/29 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.